,i #aadth ,,congress #ast ,session ,h4 ,r4 #bedg ,,in ,,the ,,house ,,of ,,representatives ,may #ba1 #bjae ,mrs4 ,mc,morris ,rodgers introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act to provide for the development of accelerated approval development plans for investigational drugs and biological products4 #a4 ,short title ,this ,act may be cited as the ,surrogate ,endpoint ,improvement and ,utilization ,act of #bjae4 #b4 ,accelerated approval development plan 7a7 ,in general ,section #ejf of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cef7 is amended by adding the following subsection3 7g7 ,accelerated approval development plan 7#a7 ,in general ,in the case of a drug determined to be eligible for accelerated approval under subsection 7c71 at any time after the submission of an application for the investigation of the drug under section #eje7;i7 of this ,act or section #cea7;a77#c7 of the ,public ,health ,service ,act1 the sponsor of such drug may voluntarily request agreement by the ,secretary to an accelerated approval development plan with respect to a surrogate endpoint to be used to study the drug4 7#b7 ,plan ,a plan described in paragraph 7#a7 shall include agreement on-- 7,a7 the surrogate endpoint to be assessed under the plan2 7,b7 the design of the study that will utilize the surrogate endpoint2 and 7,c7 the magnitude of the effect of the drug on the surrogate endpoint that is the subject of the agreement that would be sufficient to form the primary basis of a claim that the drug is effective4 7#c7 ,modification2 termination ,the ,secretary may require the sponsor of a drug that is the subject of an accelerated approval development plan to modify or terminate the plan if additional data or information indicates that-- 7,a7 the plan as originally agreed upon is no longer sufficient to demonstrate the safety and effectiveness of the drug involved2 or 7,b7 the drug is no longer eligible for accelerated approval under subsection 7c74 7#d7 ,sponsor consultation ,if the ,secretary requires the modification or termination of an accelerated approval development plan under paragraph 7#c71 the sponsor shall be granted a request for a meeting to discuss the basis of the ,secretary's decision before the effective date of the modification or termination4 7#e7 ,definition ,in this section1 the term accelerated approval development plan means a development plan agreed upon by the ,secretary and the sponsor submitting the plan that contains study parameters for the use of a surrogate endpoint that-- 7,a7 is reasonably likely to predict clinical benefit2 and 7,b7 is intended to be the basis of the accelerated approval of a drug under subsection 7c74 4 7b7 ,technical amendments ,section #ejf of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cef7 is amended-- 7#a7 by striking 7f7 ,awareness efforts and inserting 7e7 ,awareness efforts2 and 7#b7 by striking 7e7 ,construction and inserting 7f7 ,construction4